DelveInsight has launched a new report on Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva (FOP) , historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva (FOP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Fibrodysplasia Ossificans Progressiva (FOP) market report provides current treatment practices, emerging drugs, Fibrodysplasia Ossificans Progressiva (FOP) market share of the individual therapies, current and forecasted Fibrodysplasia Ossificans Progressiva (FOP) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Fibrodysplasia Ossificans Progressiva (FOP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs.
Click Here- Free sample page
Epidemiology
The Fibrodysplasia Ossificans Progressiva (FOP) epidemiology division provide insights about historical and current Fibrodysplasia Ossificans Progressiva (FOP) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Report key facts-
1. Frederick et al. conducted a study in Philadelphia, United States, titled “Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis,” which stated that the worldwide prevalence of FOP is approximately 1 in 2,000,000. Phenotypic variability in the timing and intensity of flare-ups can be a diagnostic criterion for FOP without evidence of ethnic, racial, gender, or geographic predisposition.
2. According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people.
3. As per the Delveinsight’sanalysis, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in the seven major markets was found to be 630 in 2017. In the United States total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) was found to be 293 in 2017.
Some of key major companies are working on this disease that are given below-
1. Ipsen Pharmaceuticals
2. Regeneron Pharmaceuticals
3. BioCryst Co.
Name of drugs covered which are given below-
1. Palovarotene
2. Garetosmab (REGN2477)
3. BLU-782
1. Key Insights
2. Executive Summary of Fibrodysplasia Ossificans Progressiva (FOP)
3. Competitive Intelligence Analysis for Fibrodysplasia Ossificans Progressiva (FOP)
4. Fibrodysplasia Ossificans Progressiva (FOP) : Market Overview at a Glance
4.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Share (%) Distribution in 2017
4.2. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Share (%) Distribution in 2030
5. Fibrodysplasia Ossificans Progressiva (FOP) : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Fibrodysplasia Ossificans Progressiva (FOP) Treatment and Management
8.2. Fibrodysplasia Ossificans Progressiva (FOP) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Fibrodysplasia Ossificans Progressiva (FOP) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
13. Fibrodysplasia Ossificans Progressiva (FOP) : Seven Major Market Analysis
13.1. Key Findings
13.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size in 7MM
13.3. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in the United States
15.1.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Germany
15.3.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in France
15.4.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Italy
15.5.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Spain
15.6.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in the United Kingdom
15.7.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Japan
15.8.3. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Fibrodysplasia Ossificans Progressiva (FOP)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Fibrodysplasia Ossificans Progressiva (FOP) market
- To understand the future market competition in the Fibrodysplasia Ossificans Progressiva (FOP) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Fibrodysplasia Ossificans Progressiva (FOP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Fibrodysplasia Ossificans Progressiva (FOP) market
- To understand the future market competition in the Fibrodysplasia Ossificans Progressiva (FOP) market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/